Table 1.
Patients with available index CTPAs (n = 341) | |
---|---|
Age (mean ± SD) | 56 (16) |
Male sex (n, %) | 167 (49) |
BMI (mean ± SD) | 28 (5.9) |
Unprovoked PE (n, %) | 188 (55) |
High-risk PE* (n, %) | 9 (2.6) |
A prior history of VTE (n, %) | 71 (21) |
Onset of symptoms > 2 weeks before index PE diagnosis (n, %) | 73 (21) |
Comorbidities (n, %) | |
Anaemia | 71 (21) |
COPD/asthma | 38 (11) |
Active malignancy# | 31 (9.1) |
Diabetes mellitus | 24 (7.0) |
Coronary artery disease | 22 (6.5) |
Rheumatic disease^ | 15 (4.4) |
Hypothyroidism | 14 (4.1) |
Known antiphospholipid antibodies | 5 (1.5) |
Interstitial lung disease | 4 (1.2) |
Inflammatory bowel disease | 4 (1.2) |
Major vasculitis syndromes | 2 (0.6) |
Prior infected pacemaker leads | 1 (0.3) |
Splenectomy | 1 (0.3) |
Anticoagulant treatment at 3-month follow-up visit | |
DOAC | 233 (68) |
VKA | 87 (26) |
LMWH | 29 (8.5) |
Note:
*According to the 2019 European Society of Cardiology Guidelines on Acute PE
#Active malignancy was defined as follows: diagnosis of cancer within 6 months prior to enrolment, any treatment for cancer within the previous 6 months or recurrent metastatic cancer
^Rheumatic disease was defined as follows: known rheumatic arthritis, osteoarthritis, connective tissue disease, systemic lupus erythematosus, ankylosing spondylitis or Sjögren syndrome
Abbreviations: PE, pulmonary embolism; SD, standard deviation; BMI, body mass index; VTE, venous thromboembolism; COPD, chronic obstructive pulmonary disease; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist; DOAC, direct oral anticoagulant. Anaemia was defined as: males < 8.5 mmol/L or < 13.5 g/dL; females < 7.5 mmol/L or < 12.0 g/dL